218 related articles for article (PubMed ID: 34863216)
1. Long-term safety and effectiveness of velaglucerase alfa in Gaucher disease: 6-year interim analysis of a post-marketing surveillance in Japan.
Sagara R; Ishigaki M; Otsuka M; Murayama K; Ida H; Fernandez J
Orphanet J Rare Dis; 2021 Dec; 16(1):502. PubMed ID: 34863216
[TBL] [Abstract][Full Text] [Related]
2. Velaglucerase alfa for the management of type 1 Gaucher disease.
Morris JL
Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
[TBL] [Abstract][Full Text] [Related]
3. A multicenter, open-label extension study of velaglucerase alfa in Japanese patients with Gaucher disease: Results after a cumulative treatment period of 24months.
Ida H; Tanaka A; Matsubayashi T; Murayama K; Hongo T; Lee HM; Mellgard B
Blood Cells Mol Dis; 2016 Jul; 59():140-7. PubMed ID: 27241455
[TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement and substrate reduction therapy for Gaucher disease.
Shemesh E; Deroma L; Bembi B; Deegan P; Hollak C; Weinreb NJ; Cox TM
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010324. PubMed ID: 25812601
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase.
Zimran A; Pastores GM; Tylki-Szymanska A; Hughes DA; Elstein D; Mardach R; Eng C; Smith L; Heisel-Kurth M; Charrow J; Harmatz P; Fernhoff P; Rhead W; Longo N; Giraldo P; Ruiz JA; Zahrieh D; Crombez E; Grabowski GA
Am J Hematol; 2013 Mar; 88(3):172-8. PubMed ID: 23339116
[TBL] [Abstract][Full Text] [Related]
6. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.
Smith L; Rhead W; Charrow J; Shankar SP; Bavdekar A; Longo N; Mardach R; Harmatz P; Hangartner T; Lee HM; Crombez E; Pastores GM
Mol Genet Metab; 2016 Feb; 117(2):164-71. PubMed ID: 26043810
[TBL] [Abstract][Full Text] [Related]
7. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
Ben Turkia H; Gonzalez DE; Barton NW; Zimran A; Kabra M; Lukina EA; Giraldo P; Kisinovsky I; Bavdekar A; Ben Dridi MF; Gupta N; Kishnani PS; Sureshkumar EK; Wang N; Crombez E; Bhirangi K; Mehta A
Am J Hematol; 2013 Mar; 88(3):179-84. PubMed ID: 23400823
[TBL] [Abstract][Full Text] [Related]
8. Development of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease.
Pastores GM; Turkia HB; Gonzalez DE; Ida H; Tantawy AA; Qin Y; Qiu Y; Dinh Q; Zimran A
Blood Cells Mol Dis; 2016 Jul; 59():37-43. PubMed ID: 27282565
[TBL] [Abstract][Full Text] [Related]
9. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
Pastores GM
Curr Opin Investig Drugs; 2010 Apr; 11(4):472-8. PubMed ID: 20336596
[TBL] [Abstract][Full Text] [Related]
10. A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability.
Pastores GM; Rosenbloom B; Weinreb N; Goker-Alpan O; Grabowski G; Cohn GM; Zahrieh D
Genet Med; 2014 May; 16(5):359-66. PubMed ID: 24263462
[TBL] [Abstract][Full Text] [Related]
11. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study.
Gonzalez DE; Turkia HB; Lukina EA; Kisinovsky I; Dridi MF; Elstein D; Zahrieh D; Crombez E; Bhirangi K; Barton NW; Zimran A
Am J Hematol; 2013 Mar; 88(3):166-71. PubMed ID: 23386328
[TBL] [Abstract][Full Text] [Related]
12. Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials.
Hughes DA; Gonzalez DE; Lukina EA; Mehta A; Kabra M; Elstein D; Kisinovsky I; Giraldo P; Bavdekar A; Hangartner TN; Wang N; Crombez E; Zimran A
Am J Hematol; 2015 Jul; 90(7):584-91. PubMed ID: 25801797
[TBL] [Abstract][Full Text] [Related]
13. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.
Séllos-Moura M; Barzegar S; Pan L; Shi P; Oommen S; Durant J; Ruiz JA
J Immunol Methods; 2011 Oct; 373(1-2):45-53. PubMed ID: 21846471
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.
Elstein D; Mehta A; Hughes DA; Giraldo P; Charrow J; Smith L; Shankar SP; Hangartner TN; Kunes Y; Wang N; Crombez E; Zimran A
Am J Hematol; 2015 Jul; 90(7):592-7. PubMed ID: 25776130
[TBL] [Abstract][Full Text] [Related]
15. 13,845 home therapy infusions with velaglucerase alfa exemplify safety of velaglucerase alfa and increased compliance to every-other-week intravenous enzyme replacement therapy for Gaucher disease.
Elstein D; Abrahamov A; Oz A; Arbel N; Baris H; Zimran A
Blood Cells Mol Dis; 2015 Dec; 55(4):415-8. PubMed ID: 26460268
[TBL] [Abstract][Full Text] [Related]
16. Rapid home therapy infusion of velaglucerase alfa in naïve patients with Gaucher disease.
Becker-Cohen M; Revel-Vilk S; Frydman D; Dinur T; Tiomkin M; Istaiti M; Arbel N; Bauer P; Cozma C; Rolfs A; Szer J; Zimran A
Intern Med J; 2024 Mar; 54(3):398-403. PubMed ID: 37493453
[TBL] [Abstract][Full Text] [Related]
17. Seven-year safety and efficacy with velaglucerase alfa for treatment-naïve adult patients with type 1 Gaucher disease.
Zimran A; Wang N; Ogg C; Crombez E; Cohn GM; Elstein D
Am J Hematol; 2015 Jul; 90(7):577-83. PubMed ID: 25903392
[TBL] [Abstract][Full Text] [Related]
18. The budget impact of enzyme replacement therapy in type 1 Gaucher disease in the United States.
Farahbakhshian S; Inocencio TJ; Poorman G; Wright E; Pathak RR; Bullano M
J Med Econ; 2022; 25(1):755-761. PubMed ID: 35611840
[TBL] [Abstract][Full Text] [Related]
19. Home infusion of intravenous velaglucerase alfa: Experience from pooled clinical studies in 104 patients with type 1 Gaucher disease.
Elstein D; Burrow TA; Charrow J; Giraldo P; Mehta A; Pastores GM; Lee HM; Mellgard B; Zimran A
Mol Genet Metab; 2017; 120(1-2):111-115. PubMed ID: 27614581
[TBL] [Abstract][Full Text] [Related]
20. Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience.
Zimran A; Altarescu G; Philips M; Attias D; Jmoudiak M; Deeb M; Wang N; Bhirangi K; Cohn GM; Elstein D
Blood; 2010 Jun; 115(23):4651-6. PubMed ID: 20299511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
